This site is intended for healthcare professionals

Advaxis Inc, and Biosight Ltd. to merge and trade as Biosight Therapeutics.

Read time: 1 mins
Last updated:29th Jul 2021
Published:7th Jul 2021
Advaxis, Inc. and Biosight Ltd. a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction.
Type: industry
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest